study question: Does administration of androgen to female-to-male transsexual persons (FTMs) of reproductive age induce polycystic ovary (PCO) morphology?
Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disorder associated with anovulation, elevated circulating androgens, hirsutism, obesity and insulin resistance. The aetiology of PCOS is still not completely understood, though anovulation and hirsutism are considered to be phenotypes of hyperandrogenism (Kaltsas et al., 2004; Trakakis et al., 2008) .
The role of androgen in follicle development has been controversial for some time. From animal studies, it was determined that androgens stimulate follicular development during the early stages of maturation but the effect of androgens diminishes as the follicles mature (Norbert et al., 2011) . Then, after the selection of a dominant follicle, androgens exert an atretogenic effect on the follicles (Hillier and Tetsuka, 1997) . In PCOS, early follicular growth is accelerated but the selection process is defective, resulting in maturation arrest leading to an ovulation disorder. In other words, the two roles of androgen do not work properly in women with PCOS (Jonard and Dewailly, 2004) . Although it is not entirely clear how androgen acts in PCOS, there is no doubt that excessive androgen is closely related to the pathogenesis of PCOS. In an effort to determine the significance of androgen effects in PCOS, a number of animal models involving the administration of excess androgen at various times during development have been reported (Murray et al., 1998; Vendola et al., 1998; Honnma et al., 2006; Abbott et al., 2009) . For example, rhesus monkeys exposed prenatally to androgen exhibit features similar to PCOS (Abbott et al., 2009) , while treating rhesus monkeys of reproductive age with androgen increased the number of small follicles only (Vendola et al., 1998) . In addition, the administration of dehydroepiandrosterone to juvenile rats causes the development of polycystic ovary (PCO) morphology (Honnma et al., 2006) .
On the other hand, there have been few studies of the effects of exogenous androgen in humans. In that regard, many female-to-male transsexual persons (FTMs) receive long-term treatment with androgen prior to undergoing sex-reassignment surgery (SRS). Several investigators have reported that the androgen-exposed ovaries of FTMs show PCOS-like features (Amirikia et al., 1986; Futterweit and Deligdisch, 1986; Spinder et al., 1989; Pache et al., 1991; Grynberg et al., 2010) ; that is, the ovarian cortex is thickened and shows marked collagenization, and the ovarian stroma contains greater numbers of cystic and cystic atretic follicles. In most of these reports, however, there was no attempt to objectively quantify and statistically analyse these observations. Interestingly, we recently noticed that the resected ovaries of SRS patients visiting our gender clinic did not always show a PCO morphology, despite exposure to androgen. Therefore, it is unclear whether exogenous androgen actually produces PCO morphology in humans, as it does in animal models.
The purpose of this study was to examine the effect of high doses of exogenous androgen on human ovarian morphology.
Materials and Methods

Study groups
From May 2007 through March 2011, 20 FTMs underwent SRS in our hospital, which included bilateral salpingo-oophorectomy and hysterectomy. The ovaries of 11 FTMs were evaluated histologically and these women comprised the FTM group. These 11 women had been administered 125 mg testosterone enanthate (i.m.) every 2 weeks for periods ranging from 17 months to 14 years (median: 38 months). Prior to androgen treatment, all of the FTMs had a regular menstrual cycle according to their medical history, and imaging using transrectal ultrasonography was used to evaluate ovarian morphology. None of the FTMs were diagnosed with PCOS before surgery (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) . As a control group we examined 10 age-and BMI-matched individuals who had undergone pelvic surgery (for gynaecologic malignancies) for uterine cervical cancer (n ¼ 6) and uterine endometrial cancer (n ¼ 4). All 10 control patients had a regular menstrual cycle prior to their surgery, and magnetic resonance imaging and transvaginal ultrasonography indicated that there was no ovarian metastasis or PCO morphology. Moreover, none of the resected ovaries showed evidence of metastasis on pathological examination. We thus confirmed that no one in the control group met the Rotterdam criteria (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) for PCOS. This study was approved by the institutional review board and written informed consent was obtained from all patients.
Histopathological study
The resected ovaries were fixed in 10% formalin, embedded in paraffin and longitudinal sections of 7 mm were prepared throughout the largest diameter of the ovaries. The sections were stained with hematoxylineosin using standard techniques and were examined. The pathological examination was performed by two observers. Because of heterogeneity, ovarian morphology in PCOS had not been well defined. Therefore, we used the morphology of Stein -Leventhal ovary as a reference (hyperandrogenic PCOS with PCO morphology). So the following characteristics were deemed to indicate Stein -Leventhal ovary (Hughesdon, 1982) : (i) collagenization and thickening of the tunica albuginea; (ii) stromal hyperplasia; (iii) luteinization of the stromal cells and (iv) ovaries with multiple follicles at various stages of growth and atresia. We also checked for the presence or absence of a corpus luteum and corpora albicantia, and measured the thickness of the cortex and the collagen layer at three points in both ovaries.
To count separately the numbers of follicles at different stages of development, we classified the follicles into four categories based on their maturation. The first category (C1) contained primordial follicles, which were 30 -60 mm in diameter and had flat epithelial cells. The second category (C2) contained follicles at three stages: (i) primary follicles, which were .60 mm in diameter and had a single layer of cubiform granulosa cells; (ii) pre-antral follicles, which were 0.12 -0.2 mm in diameter and had more than two layers of granulosa cells and (iii) early antral follicles, which were 0.12 -2 mm in diameter and had multiple layers of granulosa cells and a follicular antrum. These follicles classified as C2 were able to grow in the presence of androgen. The third category (C3) contained antral follicles, which were .2 mm in diameter and are known to require gonadotrophin to grow (Norbert et al., 2011) . The fourth category (C4) contained atretic follicles. We counted follicles in each category separately (number of follicles/cm 2 ).
Physical and biochemical studies
On their first visit to our hospital, FTMs provided a medical history and received psychiatric evaluation and a physical examination, including a chromosomal study. Transvaginal (controls) or transrectal (FTMs) ultrasonographic scans were performed using a 5-MHz probe. In addition, serum levels of LH and FSH were checked, and the LH/FSH ratio was calculated. Furthermore, the serum levels of free testosterone, total testosterone, androstenedione and dehydroepiandrosterone sulphate (DHEA-S) were measured by radioimmunoassay as previously described (Baba et al., 2011) . Fasting glucose and fasting insulin were checked and the homeostasis model assessment of insulin resistance (HOMA-IR) was used to calculate the insulin resistance (Legro et al., 2004) . HOMA-IR was calculated using the formula: fasting plasma glucose (mg/dl) × fasting plasma insulin (mU/ml)/405, and HOMA-IR values .2.0 were considered to indicate insulin resistance. The purpose of these examinations was to diagnose transsexualism and to exclude individuals with a chromosomal abnormality or virilizing disorder. Endocrine analysis was performed during the follicular phase of the menstrual cycle.
Statistical analysis
The histopathological findings from the FTM and control groups were compared using the Mann -Whitney U-test. Values are given as the median [interquartile range (IQR)]. We assessed the presence or absence of four histological characteristics (stromal hyperplasia, stromal luteinization, corpus luteum and corpora albicantia) and we calculated the ratio of cases having these histological characteristic. Fisher's exact probability test was used to evaluate the significance of the appearance rate. Two-sided P-values of ,0.05 were considered statistically significant (Excel Statistics, 2009 ).
Results
Biochemical and imaging studies of PCO morphology
The clinical characteristics of the individuals in the FTM group are shown in Table I . All 11 FTMs were chromosomal and phenotypic females. At their initial examination, six in the FTM group had been taking testosterone on their own prior to this study, while the remaining five had not. Correspondingly, the serum androgenic hormone levels were significantly elevated in those six FTMs taking testosterone but not in the others. Before androgen treatment, all of the FTMs had a regular menstrual cycle according to their medical history, but after beginning the androgen treatment in this study, all of them became amenorrhoeic and showed abnormally elevated serum total (^0.6 ng/ml) and free (^1.0 pg/ml) testosterone levels and hirsutism (Baba et al., 2007) . Most of them did not show elevated serum androstenedione (^3.5 ng/ml) and DHEA-S (^3500 mg/dl). In addition, only one showed excessive suppression of serum LH (,1.0 mIU/ml) and FSH (,1.5 mIU/ml), despite the androgen administration.
Two of the 11 FTMs (Case Nos. F4 and F11) exhibited PCO morphology at their initial ultrasonographic evaluation. However, neither of these women had been taking testosterone at that time and there was no evidence of elevated androgen levels. In addition, their menstrual cycles were regular, therefore they were not diagnosed as having PCOS. We also confirmed that none of the other three FTMs not taking testosterone met the Rotterdam criteria for PCOS.
Histopathological findings
The histological findings for ovaries with (FTM group) and without (control group) exposure to exogenous androgens are shown in Table II . Interestingly, the two FTMs with PCO morphology identified by ultrasound at their first evaluation (Case Nos. F4 and F11; neither fulfilled the Rotterdam criteria for PCOS) had similar numbers of C3 follicles as the other FTMs and the controls. In other words, androgen administration may have converted their PCO into non-PCO morphology (although it is also possible the initial evaluation was inaccurate). A statistical comparison of the two groups is shown in Table III . The mean thicknesses of the tunica albuginea and the collagenous layer of the tunica were significantly greater in the FTM group than that in the control group (Fig. 1E and F) . Diffuse stromal hyperplasia, luteinized stromal cells and isolated clusters of luteinized storomal cells, within the stroma were observed significantly and more frequently in the FTM group than in the control group. On the other hand, the mean density of C1-C3 follicles did not significantly differ between the FTM and control groups; however, we found that there were significantly larger numbers of C4 (atretic) follicles in the FTM group.
In this study, we observed a variety of structures composed of masses of lucent cells within the stroma of androgen-treated ovaries in FTMs (Fig. 2) . One of these structures was a dense cluster of lucent cells similar to the corpora albicantia ( Fig. 2A) and was readily distinguishable from the surrounding stroma (Fig. 2B) . Another was a collapsed cluster of cells not easily distinguishable from the surrounding stroma (Fig. 2D) . The presumed transition of both structures was also observed in the FTM group (Fig. 2C ).
Discussion
In this study, we examined the effect of androgen on ovarian morphogenesis; that is, we attempted to determine whether androgen induces PCO morphology by comparing androgenized FTMs (study group) and women (control group: with regular menstrual cycles and without PCO morphology). Insulin resistance and hypersecretion of LH, which may be modified by androgen administration, are characteristics of PCOS. However, no significant difference was observed among control and FTM groups with regard to insulin resistance and LH levels. Therefore, we could evaluate the direct effect of androgen on ovary. We showed that androgen exposure causes a thickening of the ovarian cortex, which is a sequela of subepithelial collagenization. This finding is consistent not only with earlier studies of androgen effects but also with PCOS (Goldzieher and Green, 1962; Hughesdon, 1982) . The ovarian cortex comprises a basal layer and a collagenous layer. Ovaries in the control group had a thin collagenous layer, while those in the testosterone-treated FTMs had the collagenous layer that was two to three times thicker, making the overall cortex thicker than in the controls. In contrast, there was no significant difference between the basal layers in the two groups. The observed cortex collagenization induced by exogenous androgen contributed to an enlargement of the ovaries, and this thickening of the tunica albuginea is thought to mechanically inhibit follicle rupture and ovulation, which may be one of the causes of the ovulation disorder and luteinized unruptured follicle syndrome seen in PCOS (Toda, 1990; Henmi et al., 2001) .
Hyperplasia and luteinization of the stromal and theca cells are the most common findings in testosterone-treated ovaries (Amirikia et al., 1986; Futterweit and Deligdisch, 1986; Pache et al., 1991) . In our study, stromal hyperplasia was observed in most of the FTMs but not in the controls, as previously reported (Amirikia et al., 1986; Pache et al., 1991) . Diffuse luteinization of the stroma was also observed in most of the FTMs and in three of the controls. Also within the FTM group, isolated clusters of luteinized stromal cells were observed in all of the ovaries in which diffuse stromal luteinization were observed, but clusters were not observed in the control Follicles (see Table III for further analysis): C1, primodial follicles; C2, primary follicles, pre-antral follicles, and early antral follicles; C3, antral follicles, .2 mm diameter; C4, atretic follicles. group, not even within the luteinized stroma. These stromal changes are commonly seen in patients with PCOS, and are thought to be a consequence of increased LH stimulation of the theca cells and stromal components linked to augmented androgen production (Goldzieher and Green, 1962) , which is consistent with the idea that androgen induces PCOS. In the present study, we observed a variety of lucent structures in the stroma of androgen-treated ovaries in FTMs. One of these was similar to the corpora albicantia, while another was similar to a luteinized cluster. These structures were similar to those previously observed by Pache et al. (1991) , and transition of both structures was also observed. It is therefore very difficult to classify these structures as corpora albicantia or luteinized cluster. We also observed a structure similar to a collapsed corpora albicantia in three of the FTMs, whereas a well-shaped corpora albicantia was rarely seen, contrary to findings in the control group. Spinder et al. (1989) reported that a corpora albicantia was observed in all testosterone-treated patients. Interestingly, Pache et al. (1991) did not report seeing a corpora albicantia but detected luteinized clusters in 12 of 17 androgen-treated patients. The previously observed luteinized clusters and corpora albicantia, which have highly collapsed and bright structures, may be the same as the collapsed structures observed in the present study. In those earlier studies, it was suggested that this structure might be a consequence of increased LH stimulation and subsequent androgen synthesis. However, the so-called luteinized clusters and corpora albicantia we observed in androgen-treated ovaries were very similar to the dispersed and diminished atretic follicles observed in the ovaries of patients with Stein -Leventhal syndrome (Hughesdon, 1982) . We therefore suggest that these so-called luteinized clusters and corpora albicantia may arise during the process of disruption and absorption of old atretic follicles to metamorphose defective and/or old corpora albicantia. It was reported previously that exogenous androgen increases the numbers of antral and atretic follicles (Amirikia et al., 1986; Pache et al., 1991) , causing the ovaries of testosterone-treated patients to mimic those found in PCOS (Futterweit and Deligdisch, 1986; Spinder et al., 1989; Grynberg et al., 2010) . It is our experience, however, that the ovaries of some SRS patients do not exhibit a polycystic morphology during testosterone treatment. We therefore determined the number of follicles at each maturation stage present in ovaries. We found that the numbers of primordial follicles (C1) were similar in the FTM and control groups, and that atresia was rarely observed in either groups at this stage, suggesting that exogenous androgen does not affect these parameters. During early follicular development, androgen stimulates follicular maturation because it potentiates FSH-stimulated granulosa cell growth but as follicles mature, the effect of androgen diminishes, and pituitary gonadotrophin is dominant during the late stage of maturation. At the same time, androgens serve as the precursors of oestrogens, so that the growth of primary follicles, pre-antral follicles and early antral follicles (C2) could be affected by the presence of androgen. Contrary to our expectations, our results indicate that testosterone does not affect the numbers of C2 follicles. In an animal study, Vendola et al. (1998) found that rhesus monkeys treated with testosterone or dihydrotestosterone had numerous growing pre-antral and small antral follicles up to 1 mm diameter. However, the effects of testosterone on follicles at this stage have not yet been quantified and analysed precisely in human FTMs. Consequently, there is no definitive evidence that exogenous androgen increases early stage follicles in humans, though our present data suggest that excessive androgen does not increase in the number of early stage follicles in humans, which is not consistent with PCOS. It has been suggested that, at higher concentrations, androgens are converted to 5a-androgen, which inhibits aromatase expression by granulosa cells. This would in turn reduce production of oestrogen, which is necessary for follicle growth (Gill et al., 2004) . Our findings are consistent with this scenario.
Growth of antral (C3) follicles (.2 mm), which are abundant in patients with PCOS, may be dependent on gonadotrophin. Our results also show there is no difference in the numbers of C3 follicles between the FTM and control groups. Amirikia et al. (1986) make a meaningful comparison because of the small number of follicles they observed; instead, they compared follicles at all stages (healthy antral, cystic atretic and atretic) collectively. These reports provide no firm evidence that androgen treatment increases the number of antral follicles. Other studies also provide no clear evidence of increased antral follicles with androgen treatment (Futterweit and Deligdisch, 1986; Spinder et al., 1989; Grynberg et al., 2010) . Our present results and earlier reports (Futterweit and Deligdisch, 1986; Spinder et al., 1989; Grynberg et al., 2010) indicate that long-term, high-dose testosterone treatment does not increase the number of antral follicles, as in PCO. Interestingly, the ovaries of two FTMs initially diagnosed as exhibiting PCO morphology (by transrectal ultrasound) in the absence of androgen exposure, showed a reduction in the number of cystic follicles after treatment with high-dose testosterone, and the resected ovaries did not meet the criteria for PCOS (presence of 12 or more follicles in each ovary measuring 2-9 mm diameter) (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) . In addition, none of the FTM group was diagnosed with PCOS at the time of their operation. These results are consistent with the hypothesis that excessive androgen may reduce the number of healthy cystic follicles.
We found that the number of atretic (C4) follicles was mainly increased in FTMs who had taken testosterone on their own, prior to this study. Our data and earlier human studies indicate that excessive exogenous androgen accelerates follicular atresia (Amirikia et al., 1986; Pache et al., 1991) . This finding is somewhat different from PCOS, which is not characterized by follicular atresia but by a larger follicular pool and arrest of late folliculogenesis (Jonard and Dewailly, 2004) . Thus, intrinsic (e.g. hyperandrogenic PCOS) and extrinsic (e.g. cross-sex hormone treatment in FTM) androgen may affect follicles differently. It is worth noting at what stage exogenous androgen accelerates atresia. After dividing atretic follicles into cystic atretic and atretic groups, Pache et al. (1991) concluded that the numbers of both are significantly increased by testosterone. In the present study, we grouped all atretic follicles together because it was difficult to detect follicular atresia during early growth, and the number of atretic follicles at each stage, except cystic atretic, was too small for meaningful comparison.
We recognize that our study has several limitations. First, we could not compare ovarian tissues before and after androgen administration in the same person, other than by an initial ultrasound. It therefore remains a possibility that some of the observed histopathological changes may have been present before androgen administration. Second, the number of participants in the two groups was small; however, the histopathological findings indicate a similar tendency and little divergence within both groups. Third, it is somewhat surprising that none of the FTMs participating in this study exhibited PCOS, despite the reportedly high prevalence of PCOS among FTMs generally (Baba et al., 2011) , and we think this is because the number of FTMs undergoing SRS in our hospital is relatively small. Finally, knowledge of serum anti-Mullerian hormone levels in our study groups would have been useful in relation to the follicle characteristics observed, however these data were not available.
In conclusion, our results indicate that high-dose androgen administered to FTMs of reproductive age changes the ovarian cortex and stroma, in a manner that is similar to the Stein -Leventhal ovary but it does not induce PCO morphology. That is, androgen does not increase the number of healthy follicles at all growth stages; instead it only increases the number of atretic follicles in adults. This observation is somewhat different from the data obtained in animal studies, in which prenatal androgen exposure can lead to PCOS. This discrepancy may be because the effects of high-dose androgen during adulthood differ from the effects during the fetal period.
